You are viewing the site in preview mode
Skip to main content
| |
MTX-use
|
p
|
CV-Event
|
p
|
|---|
|
Yes (n = 222)
|
No (n = 163)
|
Yes (n = 23)
|
No (n = 362)
|
|---|
|
RDW, mean(SD), %
|
14,5 (1,4)
|
14,1 (1,6)
|
< 0,001
|
15,05 (2,2)
|
14,25 (1,4)
|
0,116
|
|
Hb, mean(SD), g/l
|
134,8 (14,5)
|
132,9 (14)
|
0,101
|
130,2 (14,4)
|
134,2 (14,3)
|
0,058
|
|
CRP, mean(SD), mg/dl
|
0,65 (0,97)
|
1,03 (2,1)
|
0,559
|
0,99 (1,1)
|
0,8 (1,6)
|
0,060
|
|
ΔRDW, mean(SD)
|
0,53 (1,24)
|
0,23 (1,0)
|
0,057
|
0,45 (0,6)
|
0,43 (1,2)
|
0,809
|
- Effects of MTX intake on laboratory parameters at last visit prior to the CV event/last follow up. ΔRDW Change in RDW between initial diagnosis and follow up prior to the CV event/last follow up in patients without CV event. Hb hemoglobin level. In the overall cohort RDW at established disease was not applicable as predictive marker for a CV event. A tendency with lower hemoglobin levels and higher CRP was shown. MTX intake significantly affected RDW
